JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. - Wikidata - wikimedia - TriplyDB

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

http://www.wikidata.org/entity/Q37623539

about

Recent advances in understanding myelofibrosis and essential thrombocythemia Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors Guidelines for the management of myeloproliferative neoplasms Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs)Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.The puzzle of myeloproliferative neoplasms: novel disease-specific mutations and new proposals for diagnostic criteria Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis The Calreticulin gene and myeloproliferative neoplasms.Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and T Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms.Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome.Calreticulin exon 9 mutations in myeloproliferative neoplasms.Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.High resolution melting analysis: a rapid and accurate method to detect CALR mutations.Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome.Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution.Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia.Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden.Genetic-pathologic characterization of myeloproliferative neoplasms.Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.

P2860

Q26748543-3B79621A-D272-49C3-AA43-BDCAA1139FAC Q26766319-30FA81FA-DC89-47A7-9EC8-26CFFF774A12 Q26777265-774259F2-40A1-45CF-A3A1-9DB3408938FC Q26778326-FE28622B-2FAD-408B-99AE-F5F4CB7D0BD7 Q26799388-47A88C72-7A6E-46D4-878F-2B8B22582D44 Q26799790-3AD234E5-1C7D-4F5F-BECE-0B16EACFAAC4 Q27853043-AB220694-68F8-4EEF-ADE7-81FB490A0DB5 Q28084727-623E729B-8B1D-4F29-A2E4-AE72DA3E806E Q30235926-C94096FF-C65B-4D0C-BD40-0606C9B39763 Q31159627-3D126A3C-905F-4895-84B1-155EB9693526 Q33359793-D3C50237-733C-445B-9C77-FD3BD92679CA Q33416223-8EA91E67-067E-4774-A1B7-D00BFA6A570F Q33433481-446ADE40-9879-44D1-8AE0-A737F09AEBF0 Q33441445-878595D1-C151-4AAF-A2E0-0B96F94DE5E2 Q33572605-F72382BA-9818-4AA2-AC49-350249F1E671 Q33595912-D2577CC6-BABA-4A32-B7EA-37B648A6CE0D Q33751024-EEAF6759-9CC5-4BB9-8506-EC7E3DED41FF Q33828563-0E91BCBA-BD17-498B-84CE-071204F17303 Q34106883-A3918F12-FD99-400D-9C34-AC26E07A5311 Q34467863-F0E1CF63-1F0D-4434-B0D7-54A7F08442F2 Q34635408-91BBBF1F-DB09-4ABB-8DB0-9DB20AF7D472 Q34749671-4854B035-E811-4479-8AF8-50D0A5F06A5D Q35088483-B12EBB03-ACAA-43C7-8BA4-907B21DB183E Q35214151-29B28967-4870-4E35-94D9-0C766D172488 Q35598864-ADFD75D7-94C4-4A0C-B3DB-6FECE8935C3F Q35777306-9E63E0B7-B0CA-454A-8C6C-BD09924B7AB6 Q35778568-5B2215FE-B9B8-4440-A652-76EF3CB8DF64 Q35800819-07371A27-9A88-4715-84BD-0AB4B9755D3E Q35925679-F12C35C2-6227-4FAC-9C48-40353E02C9DE Q36261941-DC727FD3-238D-4A5D-BFAC-B70219A31321 Q36502712-F0D6A21F-455C-4B1F-AC2F-CC607E23656E Q36541323-39A8BDFF-907D-40E7-AD6A-D62F0BE26810 Q36556161-C4777CD7-C1F9-46C6-B790-B38C74062D70 Q36654317-E42C2A93-DD94-49C1-8E3C-E76A28A790B3 Q36782943-54653218-E462-4190-AB62-EA8183CF82BF Q36853951-AE084890-773E-4BD9-A093-1674B5082897 Q36864296-4F8AB579-21DA-4BB0-979E-DB13F9F31240 Q36954379-221B87B8-4FC9-4B6C-9D4C-4AC954A129C1 Q37151437-43D04239-53D0-4157-BD16-53A0DB01F42F Q37157892-9EAB3EFF-E82E-4934-AD75-FAD0F803DC53

P2860

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

http://www.wikidata.org/entity/Q37623539

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

JAK2 or CALR mutation status d ...... clinical course and outcomes.

@en

JAK2 or CALR mutation status d ...... clinical course and outcomes.

@nl

type

label

JAK2 or CALR mutation status d ...... clinical course and outcomes.

@en

JAK2 or CALR mutation status d ...... clinical course and outcomes.

@nl

prefLabel

JAK2 or CALR mutation status d ...... clinical course and outcomes.

@en

JAK2 or CALR mutation status d ...... clinical course and outcomes.

@nl

P1433

Q37623539-A5AF6A4D-90B0-450B-99DE-9C88D9EB7677

P1476

Q37623539-23F952C4-8CB6-467E-BE4C-D3C4FE9FFA89

P2093

Q37623539-0DF2B08A-1685-4B62-A0CB-10C49114802E

Q37623539-14617871-91F0-43AC-B507-4EF47D4510E8

Q37623539-2060951F-B09E-404E-8BA6-EEFFC4731429

Q37623539-4AA602D5-890F-4278-B5C0-5CA1B484082B

Q37623539-4D507B28-1AA3-4ADC-81C3-06BF4CE4F5F7

Q37623539-52FA2595-1DAE-4F50-9F4C-BCE6195918D5

Q37623539-5D2E5316-BF13-4767-9A67-DD695DB65738

Q37623539-7E6E1DCF-738A-4615-8727-3DC8A2E7C845

Q37623539-BB28921B-F0E2-457A-BC93-650523E25C7C

Q37623539-C7185144-D1A5-450C-B4F3-E361D16484E8

P2860

Q37623539-040E1549-0628-4693-B16D-6830196E3247

Q37623539-1FF066F5-7251-4840-8D5C-C0A2A69EA5A4

Q37623539-256DCED7-9E75-4EC4-9750-EA5FC1622F70

Q37623539-2FFDB4FF-9D6D-45CA-B316-ADD6FC6D2BC0

Q37623539-43E8EC41-7633-483A-9740-F6E44D228EB3

Q37623539-46D47B04-B751-4216-8BD7-59BF0995F15F

Q37623539-4CBAC9B4-4DB7-4832-832E-78A4E2765427

Q37623539-56E4D013-4E45-46E7-8CE1-17CC06592A04

Q37623539-577BB3D1-1A41-4D13-8C91-63AB82DA3664

Q37623539-6020B75E-6B84-465B-970C-01F384730C8F

P304

Q37623539-C535C306-EC79-46F2-9D52-DD4085029A42

P31

Q37623539-3B77162C-FE4B-4D4D-A569-89D6F7BCD0D4

P356

Q37623539-FECC5F62-79DF-44C8-8C70-BF449B6C1DF9

P407

Q37623539-E5CE4B8E-CA0E-407C-9DDA-97FBB589CDF5

P433

Q37623539-D03F62A6-4304-47D3-8694-309D2BF4F1E4

P478

Q37623539-4337DFEB-8C45-44E0-9F61-D549650720F2

P50

Q37623539-1E6CF38F-650C-427A-92DF-DD51400DBADF

Q37623539-2895368A-2283-4D21-B468-1BD1E09B8880

Q37623539-5DA6ECBA-3E4F-4D31-8368-BC6BBA3A1A3D

Q37623539-936B824F-1155-4957-8980-9F3886F5846B

Q37623539-BFE5F8D5-CC87-4FA2-B404-860DF143EA22

Q37623539-D40E4D2A-1C8A-4343-A088-764E163BDD3D

Q37623539-DB46AEAA-6F0B-4170-97FC-14A10FA68F57

P577

Q37623539-56A2AFB5-4C99-41C6-BC6D-3A87D60B5573

P5875

Q37623539-401CFACD-1DD8-4C02-B053-0CB1FC18A4D5

P698

Q37623539-1668B4E8-06CE-4DDE-89C1-84E079D5E0D4

P932

Q37623539-F295364B-CAFA-437F-9BBC-094B8FE2C213

P356

BLOOD-2013-11-539098

P1433

P1476

JAK2 or CALR mutation status d ...... t clinical course and outcomes

@en

P2093

Associazione Italiana per la R ...... eloproliferative Investigators

http://www.w3.org/2001/XMLSchema#string

Cesare Astori

http://www.w3.org/2001/XMLSchema#string

Chiara Elena

http://www.w3.org/2001/XMLSchema#string

Cristiana Pascutto

http://www.w3.org/2001/XMLSchema#string

Elisa Rumi

http://www.w3.org/2001/XMLSchema#string

Emanuela Boveri

http://www.w3.org/2001/XMLSchema#string

Emanuela Sant'antonio

http://www.w3.org/2001/XMLSchema#string

Ilaria C Casetti

http://www.w3.org/2001/XMLSchema#string

Maria C Renna

http://www.w3.org/2001/XMLSchema#string

Mario Cazzola

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

The World Health Organization (WHO) classification of the myeloid neoplasms

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

A gain-of-function mutation of JAK2 in myeloproliferative disorders

European consensus on grading bone marrow fibrosis and assessment of cellularity.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling

JAK/STAT signaling in hematological malignancies.

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

P304

1544-1551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-11-539098

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Robert Kralovics

Ashot S Harutyunyan

Virginia Ferretti

Chiara Milanesi

P577

2013-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259456176

http://www.w3.org/2001/XMLSchema#string

P698

24366362

http://www.w3.org/2001/XMLSchema#string

P932

3945864

http://www.w3.org/2001/XMLSchema#string